论文部分内容阅读
肿瘤细胞内谷胱甘肽增加与含铂类、烷化剂及含醌类等抗癌药物的耐药性有关.本文用谷胱甘肽还原酶循环法(Glutathione Reductase Recycling Assay)测定40例正常人,20例化疗前恶性肿瘤病人及20例以顺铂、环磷酰胺及阿霉素为主的化疗病人的血浆谷胱甘肽含量.化疗后病人血浆谷胱甘肽含量比正常人及化疗前者明显增高(P<0.01),而化疗前病人与正常人无显著差异(P>0.05).提示血浆谷胱甘肽增高与长期运用顺铂、环磷酰胺及阿霉素等药有关.5例临床产生耐药者血浆谷胱甘肽明显高于化疗组平均值(P<0.01),故可能与临床耐药有一定相关性.
The increase of glutathione in tumor cells is related to the resistance of anticancer drugs containing platinum, alkylating agents and steroids. In this article, 40 cases of normal glutathione reductase Assay were measured. Human, 20 patients with pre-chemotherapy malignant tumors and 20 patients with cisplatin, cyclophosphamide, and adriamycin-based chemotherapy patients plasma glutathione content. Plasma glutathione levels after chemotherapy compared with normal people and chemotherapy The former was significantly higher (P<0.01), but there was no significant difference between the patients before chemotherapy and normal individuals (P>0.05). It suggested that the increase of plasma glutathione was related to the long-term use of drugs such as cisplatin, cyclophosphamide and doxorubicin.5 The plasma glutathione levels in clinically resistant patients were significantly higher than those in the chemotherapy group (P<0.01), which may have a certain correlation with clinical drug resistance.